Dec 13, 2019
NCT03850522: Phase 2: PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma
NCT03850522: Phase 2: PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma PD-L1 Peptide Vaccination in High Risk...
67
Dec 31, 2018
NCT03631043: Phase 1 - Personalized Vaccine in Treating Participants With Smoldering MM
Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma This early phase I trial studies the side effects of...
332